From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
J Infect Dis
; 228(Suppl 3): S211-S220, 2023 09 13.
Article
en En
| MEDLINE
| ID: mdl-37703346
ABSTRACT
Italy has had the highest prevalence of hepatitis C virus (HCV) infection and mortality from HCV-related liver cancer in Europe. Although direct-acting antivirals (DAA) were initially restricted to persons with advanced fibrosis, their use has since been extended to all infected individuals; more than 244 000 persons have been treated to date. HCV liver-related mortality is expected to decline by 75% by 2030, achieving the World Health Organization target for mortality. However, Italy risks failing to meet the overall goal of eliminating HCV infection by 2030. In this light, 71.5 million have been allocated for screening initially specific target populations (persons who inject drugs, prison inmates, and the 1969-1989 birth cohort). Herein, we outline the challenges and recommendations for how to move Italy toward HCV elimination, including expanding screening programs in other populations, increasing awareness through strategic communication, sustaining DAA access, and tailoring care models to meet the needs of key populations.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Abuso de Sustancias por Vía Intravenosa
/
Hepatitis C
/
Hepatitis C Crónica
/
Consumidores de Drogas
Tipo de estudio:
Risk_factors_studies
Límite:
Humans
País como asunto:
Europa
Idioma:
En
Año:
2023
Tipo del documento:
Article